Amgen Inc. (AMGN): Price and Financial Metrics

Amgen Inc. (AMGN)

Today's Latest Price: $223.46 USD

1.43 (-0.64%)

Updated Oct 27 6:55pm

Add AMGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

AMGN Stock Summary

  • With a market capitalization of $131,716,673,060, Amgen Inc has a greater market value than 98.54% of US stocks.
  • AMGN's went public 34.84 years ago, making it older than 92.89% of listed US stocks we're tracking.
  • The volatility of Amgen Inc's share price is greater than that of merely 2.64% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Amgen Inc are TXN, AZN, LLY, BMY, and SAP.
  • AMGN's SEC filings can be seen here. And to visit Amgen Inc's official web site, go to

AMGN Stock Price Chart Interactive Chart >

Price chart for AMGN

AMGN Price/Volume Stats

Current price $223.46 52-week high $264.97
Prev. close $224.89 52-week low $177.05
Day low $223.14 Volume 1,934,300
Day high $225.95 Avg. volume 2,865,344
50-day MA $243.17 Dividend yield 2.86%
200-day MA $231.94 Market Cap 130.88B

Amgen Inc. (AMGN) Company Bio

Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.

AMGN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$223.46$193.25 -14%

Below please find a table outlining a discounted cash flow forecast for AMGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amgen Inc ranked in the 43th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 13.67%. As for the metrics that stood out in our discounted cash flow analysis of Amgen Inc, consider:

  • As a business, AMGN is generating more cash flow than 95% of positive cash flow stocks in the Healthcare.
  • Amgen Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than just 18.87% of tickers in our DCF set.
  • AMGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than just 18.87% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Amgen Inc? See IART, DXCM, FONR, PRAH, and RSCF.

AMGN Latest News Stream

Event/Time News Detail
Loading, please wait...

AMGN Latest Social Stream

Loading social stream, please wait...

View Full AMGN Social Stream

Latest AMGN News From Around the Web

Below are the latest news stories about Amgen Inc that investors may wish to consider to help them evaluate AMGN as an investment opportunity.

Amgen Inc., Apple Inc. share losses lead Dow's 75-point drop

The Dow Jones Industrial Average is declining Friday afternoon with shares of Amgen Inc. and Apple Inc. facing the biggest drops for the price-weighted…

MarketWatch | October 2, 2020

Wearable Injectors Market 2020 Research and New Innovations in Medical Sector- Amgen, Becton, Dickinson and Company, Dexcom, Insulet Corporation

Oct 02, 2020 (Market Insight Reports) -- This Global Wearable Injectors Market Research Report Forecast 2020-2025 is a valuable source of insightful data for…

MarketWatch | October 2, 2020

Global Gene Delivery Systems Market Research Report 2020 Featuring Amgen, Bayer, Human Stem Cells Institute, J&J, Novartis, Oxford, Biomedica, Pfizer, Shanghai Sunway Biotech, Sibiono GeneTech -

DUBLIN--(BUSINESS WIRE)--The "Gene Delivery Systems - Global Market Trajectory & Analytics" report has been added to's offering. Global Gene Delivery Systems Market to Reach $4 Billion by 2027 Amid the COVID-19 crisis, the global market for Gene Delivery Systems estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at a CAGR of 6.4% over the period 2020-2027. Viral Gene Delivery, one of the segments analyze

Business Wire | October 2, 2020

Future Aspects in Rheumatoid Arthritis Drugs Market 2020, top companies profiled like Amgen Inc., Celgene Corporation, Boehringer Ingelheim GmbH, and more

Rheumatoid Arthritis Drugs Market The Global Rheumatoid Arthritis Drugs Market report gives a comprehensive overview of the Rheumatoid Arthritis Drugs market scenario to present accurate forecasts of the upcoming years with special focus on the competitive landscape, market segmentation, current

OpenPR | October 1, 2020

Psoriasis Drugs Market Comprehensive Growth 2020-2027 with Top key vendor Amgen, AbbVie, Novartis AG, etc

The market report study titled ‘Global Psoriasis Drugs Market Report’ published by Reports and Data offers in-depth and comprehensive research describing the scope of the market and market insights until 2027. The report will include details about potential opportunities, new

OpenPR | October 1, 2020

Read More 'AMGN' Stories Here

AMGN Price Returns

1-mo -9.54%
3-mo -8.61%
6-mo -1.95%
1-year 9.86%
3-year 38.97%
5-year 62.19%
YTD -5.39%
2019 27.60%
2018 15.23%
2017 22.27%
2016 -7.56%
2015 3.96%

AMGN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AMGN Dividend History

Continue Researching AMGN

Want to see what other sources are saying about Amgen Inc's financials and stock price? Try the links below:

Amgen Inc (AMGN) Stock Price | Nasdaq
Amgen Inc (AMGN) Stock Quote, History and News - Yahoo Finance
Amgen Inc (AMGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7698 seconds.